目的 观察消癌解毒方联合R-CHOP样方案治疗初诊弥漫大B细胞淋巴瘤的临床疗效。方法 将40例弥漫大B细胞淋巴瘤患者采用随机数字表法随机分为治疗组与对照组，每组20例，治疗组采用消癌解毒方联合一线R-CHOP样方案，对照组单纯采用R-CHOP样方案，两组均化学治疗6个周期。比较两组患者临床疗效、生活质量变化及中医临床证候改善情况。结果 两组实体瘤疗效比较，差异无统计学意义（P＞0.05）。与治疗前比较，两组患者治疗后卡氏功能状态（Karnofsky performance status, KPS）评分显著升高(P＜0.05)，中医证候积分显著降低（P＜0.05），治疗组患者KPS评分升高程度和中医证候积分降低程度均显著大于对照组(P＜0.05)。两组患者不良反应发生率比较，差异无统计学意义(P＞0.05)。结论 消癌解毒方联合R-CHOP样方案治疗弥漫大B细胞淋巴瘤有助于改善患者临床症状，提高患者生活质量。
Objective To investigate the clinical efficacy of Xiaoai Jiedu prescription combined with R-CHOP-like chemotherapy regimen in the treatment of diffuse large B-cell lymphoma. Methods A total of 40 patients with diffuse large B-cell lymphoma were divided into treatment group and control group using a random number table, with 20 patients in each group. The patients in the treatment group were given Xiaoai Jiedu prescription combined with the first-line R-CHOP-like chemotherapy regimen, and those in the control group were given R-CHOP-like chemotherapy regimen alone; both groups were treated for 6 cycles of chemotherapy. The two groups were compared in terms of clinical outcome, quality of life, and traditional Chinese medicine (TCM) syndrome. Results There was no significant difference in the treatment outcome of solid tumor between the two groups (P>0.05). After treatment, both groups had a significant increase in Karnofsky performance scale (KPS) score (P<0.05) and a significant reduction in TCM syndrome score (P<0.05), and compared with the control group, the treatment group had a significantly greater increase in KPS score and a significantly greater reduction in TCM syndrome score (P<0.05). There was no significant difference in the incidence rate of adverse events between the two groups (P>0.05). Conclusion Xiaoai Jiedu prescription combined with R-CHOP-like chemotherapy regimen can improve clinical symptoms and quality of life in the treatment of diffuse large B-cell lymphoma.
〗孔祥图,于 慧,陈晓丽,姜鹏君,徐小梦,白 洁,倪海雯.消癌解毒方联合R-CHOP样方案治疗弥漫大B细胞淋巴瘤临床观察[J].安徽中医药大学学报,2021,40(2):35-39复制